{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T14:34:08Z","timestamp":1768746848362,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1093\/annonc\/mds115","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:30:15Z","timestamp":1339479015000},"page":"1943-1953","source":"Crossref","is-referenced-by-count":104,"title":["Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Albiges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Chamming's","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Camus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds115_bb0010","first-page":"3312","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0015","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal-cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0020","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0025","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0030","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds115_bb0035","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma. Final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mds115_bb0040","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"Camus","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds115_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.cco.0000228733.55132.ea","article-title":"Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)","volume":"18","author":"De Castro","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0050","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary complications of novel antineoplastic agents for solid tumors","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"key":"10.1093\/annonc\/mds115_bb0055","unstructured":"Pneumotox Website1997http:\/\/www.pneumotox.com (17 April 2012, date last accessed). Producers: Pascal Foucher, Philippe Camus, and the GEPPI"},{"key":"10.1093\/annonc\/mds115_bb0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000087945","article-title":"Patterns of pulmonary complications associated with sirolimus","volume":"73","author":"Chhajed","year":"2006","journal-title":"Respiration"},{"key":"10.1093\/annonc\/mds115_bb0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mds115_bb0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","article-title":"Signaling pathways in renal cell carcinoma","volume":"10","author":"Banumathy","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mds115_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1093\/annonc\/mds115_bb0080","doi-asserted-by":"crossref","first-page":"758s","DOI":"10.1158\/1078-0432.CCR-06-1986","article-title":"The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer","volume":"13","author":"Cho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds115_bb0085","first-page":"671","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nature Rev"},{"key":"10.1093\/annonc\/mds115_bb0090","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2009.10.013","article-title":"Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma","volume":"36","author":"Hudes","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0095","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds115_bb0100","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"2009","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0105","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","volume":"50","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mds115_bb0110","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mds115_bb0115","first-page":"viii4","article-title":"Randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3)","volume":"21","author":"Yao","year":"2010","journal-title":"Ann Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mds115_bb0120","first-page":"viii4","article-title":"Randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus\u00a0+\u00a0octreotide LAR vs placebo\u00a0+\u00a0octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2)","volume":"21","author":"Pavel","year":"2010","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mds115_bb0125","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1053\/j.seminoncol.2009.10.010","article-title":"Evaluating temsirolimus activity in multiple tumors: a review of clinical trials","volume":"36","author":"Dancey","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mds115_bb0135","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds115_bb0140","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds115_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","article-title":"The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents","volume":"4","author":"Sankhala","year":"2009","journal-title":"Targ Oncol"},{"key":"10.1093\/annonc\/mds115_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","article-title":"Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma","volume":"21","author":"Rodriguez-Pascual","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mds115_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4137\/CMO.S1590","article-title":"Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors","volume":"4","author":"Pal","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"10.1093\/annonc\/mds115_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14740330903530663","article-title":"Safety profile of new anticancer drugs","volume":"9","author":"Mansi","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1093\/annonc\/mds115_bb0165","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mds115_bb0170","unstructured":"Committee for Medicinal Products for Human Use (CHMP)\u2014European Medicines Agency. CHMP assessment report for Afinitor. May 2009"},{"key":"10.1093\/annonc\/mds115_bb0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","article-title":"Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients","volume":"72","author":"Morelon","year":"2001","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mds115_bb0180","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mds115_bb0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/modpathol.2008.189","article-title":"Cathepsin-k expression in pulmonary lymphangio-leiomyomatosis","volume":"22","author":"Chilosi","year":"2009","journal-title":"Modern Pathol"},{"key":"10.1093\/annonc\/mds115_bb0190","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0195","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0200","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0205","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds115_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8514","article-title":"Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e13520","article-title":"Mammalian target of rapamycin (mTOR)-induced pneumonitis: single-institution experience and treatment","volume":"28","author":"Kahn","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0220","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"S2","key":"10.1093\/annonc\/mds115_bb0225","article-title":"Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis","volume":"7","author":"Albiges","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds115_bb0230","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0235","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds115_bb0240","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds115_bb0245","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","article-title":"Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)","volume":"4","author":"White","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mds115_bb0250","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","article-title":"Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer","volume":"28","author":"Doi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0255","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mds115_bb0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0265","first-page":"361","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0270","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s10637-010-9624-y","article-title":"Everolimus-related organizing pneumonia: a report establishing causality","volume":"30","author":"Frija","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mds115_bb0275","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mds115_bb0280","article-title":"Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings, and correlation with clinical outcome","volume":"29","author":"Dabydeen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds115_bb0285","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","article-title":"Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients","volume":"144","author":"Champion","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mds115_bb0290","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfm420","article-title":"Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome\u2014a single-centre experience and review of the literature","volume":"22","author":"Weiner","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mds115_bb0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1432-2277.2009.00900.x","article-title":"Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options","volume":"23","author":"Schrader","year":"2010","journal-title":"Transplant Int"},{"key":"10.1093\/annonc\/mds115_bb0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.transproceed.2006.01.052","article-title":"Resolution of sirolimus-induced pneumonitis after conversion to everolimus","volume":"38","author":"Rehm","year":"2006","journal-title":"Transplantation Proc"},{"issue":"suppl 2","key":"10.1093\/annonc\/mds115_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","article-title":"Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies","volume":"16","author":"Ravaud","year":"2011","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds115_bb0310","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds115_bb0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1148\/radiol.11092149","article-title":"Imaging of pulmonary viral pneumonia","volume":"260","author":"Franquet","year":"2011","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mds115_bb0320","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1188\/11.ONF.125-128","article-title":"Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus","volume":"38","author":"Creel","year":"2011","journal-title":"Oncol Nurs Forum"},{"key":"10.1093\/annonc\/mds115_bb0325","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.hoc.2011.05.001","article-title":"Future directions in renal cell carcinoma: 2011 and beyond","volume":"25","author":"Cho","year":"2011","journal-title":"Hematol Oncol Clin N Am"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/8\/1943\/318096\/mds115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:21:59Z","timestamp":1714033319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419381244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0923753419381244"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds115","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}